報價延遲最少15分鐘:2025/05/13 12:45 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.205 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.38/-0.12
|
|
企業價值
642.26M
|
| 資產負債 |
|
每股賬面淨值
0.51
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.17M
|
|
每股收益
0.12
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 12:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |